Literature DB >> 1697384

QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions.

L Carlsson1, O Almgren, G Duker.   

Abstract

When low doses of clofilium were administered to conscious rabbits, ventricular tachyarrhythmia (VT) with features typical of torsades de pointes developed. This arrhythmia was further studied and characterized in chloralose-anesthetized rabbits. In 20 of 20 rabbits, VT developed after a mean cumulative dose of 0.53 +/- 0.04 mumol/kg clofilium, provided an infusion of the alpha 1-agonist methoxamine (15 micrograms/kg/min) was given concomitantly. The arrhythmia was preceded by a marked prolongation of the QTU interval and the monophasic action potential duration, as well as signs of early afterdepolarizations (EADs). In seven of 10 rabbits receiving only clofilium (cumulative dose, 20.8 mumol/kg), no VT occurred (p less than 0.001 compared to the incidence in animals given both methoxamine and clofilium). In animals given both methoxamine and clofilium, pretreatment with prazosin (1 mg/kg i.v., n = 4) attenuated the arrhythmia, whereas diltiazem (0.5 mg/kg i.v., n = 4) or propranolol (0.5 mg/kg i.v., n = 8) was ineffective. Acute intervention with prazosin, isoproterenol, pinacidil, or magnesium sulfate promptly regularized the rhythm in animals with VT. Prazosin and pinacidil were equally effective in beta-blocked rabbits. When other agents known to retard the repolarization currents (sematilide, UK-68,798, LY97119, amperozide, and cesium chloride) were examined, a strong correlation (r = 0.99, p less than 0.001) between the potency of the drug to prolong the QTU interval and the proarrhythmic potential was obtained. This experimental model may represent an appropriate alternative for studying the acquired ("pause-dependent') long QT syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697384     DOI: 10.1097/00005344-199008000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  32 in total

Review 1.  Effects of H1 antihistamines on animal models of QTc prolongation.

Authors:  J Gras; J Llenas
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 2.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Use-dependent block of the delayed K+ current in rabbit ventricular myocytes.

Authors:  E Carmeliet
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

4.  Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study.

Authors:  S Dhein; M Schott; E Gottwald; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

5.  Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes.

Authors:  H Nakaya; N Tohse; Y Takeda; M Kanno
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

Review 6.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

Review 7.  Genetics of acquired long QT syndrome.

Authors:  Dan M Roden; Prakash C Viswanathan
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

8.  Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967.

Authors:  Serge Sicouri; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2013-03-22       Impact factor: 6.343

9.  Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model.

Authors:  A Farkas; J Dempster; S J Coker
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 10.  Pharmacological characteristics and clinical applications of K201.

Authors:  Noboru Kaneko; Ryuko Matsuda; Yoshihito Hata; Ken Shimamoto
Journal:  Curr Clin Pharmacol       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.